Literature DB >> 21041510

Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.

Sunwen Chou1, Terry L Bowlin.   

Abstract

Among the 7 most common UL97 mutations encountered in ganciclovir-resistant clinical cytomegalovirus isolates, the associated cyclopropavir cross-resistance varies from insignificant (L595S) to substantial (M460I and H520Q) as determined by recombinant phenotyping. Mutations M460I and H520Q were preferentially selected in vitro under cyclopropavir and conferred 12- to 20-fold increases in 50% effective concentration (EC(50)) values, while M460V, C592G, A594V, and C603W conferred 3- to 5-fold increases. Uncommon mutations M460T and C603R increased cyclopropavir EC(50)s by 8- to 10-fold.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21041510      PMCID: PMC3019618          DOI: 10.1128/AAC.01259-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.

Authors:  Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

2.  Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.

Authors:  Sunwen Chou; Laura C Van Wechel; Heather M Lichy; Gail I Marousek
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  International consensus guidelines on the management of cytomegalovirus in solid organ transplantation.

Authors:  Camille N Kotton; Deepali Kumar; Angela M Caliendo; Anders Asberg; Sunwen Chou; David R Snydman; Upton Allen; Atul Humar
Journal:  Transplantation       Date:  2010-04-15       Impact factor: 4.939

4.  In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication.

Authors:  Earl R Kern; Nicole L Kushner; Caroll B Hartline; Stephanie L Williams-Aziz; Emma A Harden; Shaoman Zhou; Jiri Zemlicka; Mark N Prichard
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 5.  Antiviral drug resistance of human cytomegalovirus.

Authors:  Nell S Lurain; Sunwen Chou
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

6.  Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections.

Authors:  Earl R Kern; Deborah J Bidanset; Caroll B Hartline; Zhaohua Yan; Jiri Zemlicka; Debra C Quenelle
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

7.  Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides.

Authors:  Shaoman Zhou; Julie M Breitenbach; Katherine Z Borysko; John C Drach; Earl R Kern; Elizabeth Gullen; Yung-Chi Cheng; Jiri Zemlicka
Journal:  J Med Chem       Date:  2004-01-29       Impact factor: 7.446

8.  (Z)- and (E)-2-(1,2-dihydroxyethyl)methylenecyclopropane analogues of 2'-deoxyadenosine and 2'-deoxyguanosine. Synthesis of all stereoisomers, absolute configuration, and antiviral activity.

Authors:  Shaoman Zhou; John C Drach; Mark N Prichard; Jiri Zemlicka
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

9.  Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.

Authors:  Sunwen Chou; Gail I Marousek
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

10.  Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir.

Authors:  Brian G Gentry; Jeremy P Kamil; Donald M Coen; Jiri Zemlicka; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

  10 in total
  24 in total

Review 1.  Progress in the development of new therapies for herpesvirus infections.

Authors:  Nathan B Price; Mark N Prichard
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

Review 2.  The biology of cytomegalovirus drug resistance.

Authors:  Morgan Hakki; Sunwen Chou
Journal:  Curr Opin Infect Dis       Date:  2011-12       Impact factor: 4.915

3.  Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.

Authors:  Sunwen Chou; Ronald J Ercolani; Gail Marousek; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

4.  Advances in the Development of Therapeutics for Cytomegalovirus Infections.

Authors:  Edward Acosta; Terry Bowlin; Jennifer Brooks; Lillian Chiang; Islam Hussein; David Kimberlin; Lawrence M Kauvar; Randi Leavitt; Mark Prichard; Richard Whitley
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

5.  Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.

Authors:  Sunwen Chou; Gail Marousek; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

6.  Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.

Authors:  Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

7.  Potency and Stereoselectivity of Cyclopropavir Triphosphate Action on Human Cytomegalovirus DNA Polymerase.

Authors:  Han Chen; Chengwei Li; Jiri Zemlicka; Brian G Gentry; Terry L Bowlin; Donald M Coen
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

8.  The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.

Authors:  Elisabeth A Pitt; Pranay Dogra; Ravi S Patel; Angela Williams; Jonathan S Wall; Tim E Sparer
Journal:  Antiviral Res       Date:  2016-09-25       Impact factor: 5.970

9.  Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells.

Authors:  Brian G Gentry; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

10.  Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97.

Authors:  Brian G Gentry; Laura E Vollmer; Ellie D Hall; Katherine Z Borysko; Jiri Zemlicka; Jeremy P Kamil; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.